TORRENT PHARMACEUTICALS
Quarterly Results Analysis [Mar2025]
TORRENT PHARMACEUTICALS Quarterly Results
Consolidated | Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,959 Cr | ₹2,809 Cr | ₹2,889 Cr | ₹2,859 Cr | ₹2,745 Cr | ₹2,732 Cr | ₹2,660 Cr | ₹2,591 Cr |
Expenses | ₹1,995 Cr | ₹1,895 Cr | ₹1,950 Cr | ₹1,955 Cr | ₹1,862 Cr | ₹1,863 Cr | ₹1,835 Cr | ₹1,800 Cr |
Operating Income | ₹964 Cr | ₹914 Cr | ₹939 Cr | ₹904 Cr | ₹883 Cr | ₹869 Cr | ₹825 Cr | ₹791 Cr |
Other Income | ₹-18 Cr | ₹33 Cr | ₹-16 Cr | ₹24 Cr | ₹31 Cr | ₹-33 Cr | ₹26 Cr | ₹34 Cr |
Interest | ₹56 Cr | ₹57 Cr | ₹64 Cr | ₹75 Cr | ₹80 Cr | ₹80 Cr | ₹91 Cr | ₹103 Cr |
Depreciation | ₹201 Cr | ₹199 Cr | ₹198 Cr | ₹197 Cr | ₹203 Cr | ₹213 Cr | ₹201 Cr | ₹191 Cr |
Profit Before Tax | ₹665 Cr | ₹691 Cr | ₹661 Cr | ₹656 Cr | ₹631 Cr | ₹631 Cr | ₹559 Cr | ₹531 Cr |
Profit After Tax | ₹498 Cr | ₹503 Cr | ₹453 Cr | ₹457 Cr | ₹449 Cr | ₹443 Cr | ₹386 Cr | ₹378 Cr |
EPS | ₹14.71 | ₹14.86 | ₹13.38 | ₹13.50 | ₹13.27 | ₹13.09 | ₹11.40 | ₹11.17 |
Industry Peers & Returns | 1W | 1M | 1Y |
TORRENT PHARMACEUTICALS | 2.7% | -0.6% | 14.4% |
SUN PHARMACEUTICAL INDUSTRIES | 1.4% | 0.1% | 13.9% |
DIVIS LABORATORIES | 0.8% | 12.3% | 47.2% |
CIPLA | 2.6% | -0.1% | 0.6% |
DR REDDYS LABORATORIES | 7.8% | 12.9% | 13.3% |
MANKIND PHARMA | 1.3% | -4.8% | 9.3% |
ZYDUS LIFESCIENCES | 5.4% | 11% | -7.3% |
LUPIN | 3.3% | -1.7% | 22.3% |
AUROBINDO PHARMA | 2.8% | -2.9% | -8.3% |
TORRENT PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 5.34 % |
Y-o-Y | 7.80 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹2,959 Cr | 5.34 | |
Dec2024 | ₹2,809 Cr | -2.77 | |
Sep2024 | ₹2,889 Cr | 1.05 | |
Jun2024 | ₹2,859 Cr | 4.15 | |
Mar2024 | ₹2,745 Cr | 0.48 | |
Dec2023 | ₹2,732 Cr | 2.71 | |
Sep2023 | ₹2,660 Cr | 2.66 | |
Jun2023 | ₹2,591 Cr | - |
TORRENT PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 5.47 % |
Y-o-Y | 9.17 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹964 Cr | 5.47 | |
Dec2024 | ₹914 Cr | -2.66 | |
Sep2024 | ₹939 Cr | 3.87 | |
Jun2024 | ₹904 Cr | 2.38 | |
Mar2024 | ₹883 Cr | 1.61 | |
Dec2023 | ₹869 Cr | 5.33 | |
Sep2023 | ₹825 Cr | 4.30 | |
Jun2023 | ₹791 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 0.12 % |
Y-o-Y | 1.27 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 32.58% | 0.12 | |
Dec2024 | 32.54% | 0.12 | |
Sep2024 | 32.5% | 2.78 | |
Jun2024 | 31.62% | -1.71 | |
Mar2024 | 32.17% | 1.13 | |
Dec2023 | 31.81% | 2.55 | |
Sep2023 | 31.02% | 1.60 | |
Jun2023 | 30.53% | - |
TORRENT PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -0.99 % |
Y-o-Y | 10.91 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹498 Cr | -0.99 | |
Dec2024 | ₹503 Cr | 11.04 | |
Sep2024 | ₹453 Cr | -0.88 | |
Jun2024 | ₹457 Cr | 1.78 | |
Mar2024 | ₹449 Cr | 1.35 | |
Dec2023 | ₹443 Cr | 14.77 | |
Sep2023 | ₹386 Cr | 2.12 | |
Jun2023 | ₹378 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -6.03 % |
Y-o-Y | 2.87 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 16.83 % | -6.03 | |
Dec2024 | 17.91 % | 14.22 | |
Sep2024 | 15.68 % | -1.88 | |
Jun2024 | 15.98 % | -2.32 | |
Mar2024 | 16.36 % | 0.86 | |
Dec2023 | 16.22 % | 11.78 | |
Sep2023 | 14.51 % | -0.55 | |
Jun2023 | 14.59 % | - |
TORRENT PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -1.01 % |
Y-o-Y | 10.85 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹14.71 | -1.01 | |
Dec2024 | ₹14.86 | 11.06 | |
Sep2024 | ₹13.38 | -0.89 | |
Jun2024 | ₹13.5 | 1.73 | |
Mar2024 | ₹13.27 | 1.38 | |
Dec2023 | ₹13.09 | 14.82 | |
Sep2023 | ₹11.4 | 2.06 | |
Jun2023 | ₹11.17 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD